Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based medical device company Insightec Ltd, a leader in magnetic resonance (MR)-guided Focused Ultrasound equipment. This partnership aims to apply Insightec’s advanced Focused Ultrasound brain therapy technology for the treatment of idiopathic tremors and Parkinson’s disease in China. The collaboration marks a significant step towards providing non-invasive treatment options for neurological conditions in the country.
Focus on Non-Invasive Brain Therapy
The MR-guided focused ultrasound brain therapy system, which was approved in China in 2021, has already received marketing approvals in Europe and the United States. This system is a non-invasive surgical option for the treatment of drug-resistant idiopathic tremor and Parkinson’s disease, where tremor is the predominant symptom. It combines the precision of focused ultrasound with the detailed imaging capabilities of magnetic resonance imaging (MRI), offering a cutting-edge approach to neurological treatment.
Integration of Focused Ultrasound and MRI
The integration of focused ultrasound and MRI in this system allows for the targeting and treatment of deep tissues without the need for incisions, revolutionizing the way idiopathic tremors and Parkinson’s disease are managed. This technology provides a less invasive alternative to traditional surgical procedures, potentially reducing recovery time and risk for patients.-Fineline Info & Tech
